title: Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case.
abstract: A 60-year-old man underwent sigmoid loop colostomy for obstructive rectal cancer. Computed tomography (CT) showed a circumferential thickening of the lower rectal wall caused by a tumor invading the posterior and side pelvic wall. As we considered R0 resection too difficult, we gave the patient bevacizumab plus FOLFOX4 (oxaliplatin, leucovorin, and 5-fluorouracil). After eight courses, CT showed improvement in the rectal wall thickening but linear thickening of the mesorectal fascia remained. We therefore gave the patient chemoradiotherapy (CRT), and then 10 weeks later performed Hartmann's operation laparoscopically. Microscopic examination revealed that the tumor had been almost replaced by fibrous tissue, with only a few cancer cells left in the subserosa. The circumferential resection margin was free of cancer cells. The patient is doing well after 27 months of follow-up. This case suggests that systemic chemotherapy with FOLFOX4 plus bevacizumab prior to conventional preoperative CRT is a promising strategy for patients with initially unresectable locally advanced rectal cancer.
authors.affiliation: Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Itatani
authors.forename: Takashi
authors.initials: T
authors.lastname: Akiyoshi
authors.forename: Hiroya
authors.initials: H
authors.lastname: Kuroyanagi
authors.forename: Keiko
authors.initials: K
authors.lastname: Yamakawa
authors.forename: Rota
authors.initials: R
authors.lastname: Noaki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Konishi
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Masashi
authors.initials: M
authors.lastname: Ueno
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Oya
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Suenaga
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Yamaguchi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010388:Pelvis / Q000473:pathology; D012004:Rectal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D014057:Tomography, X-Ray Computed
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil
references.citation: Lancet. 1986 Jun 28;1(8496):1479-82
references.pmid: 2425199
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6617-23
references.pmid: 18006762
references.citation: Ann Oncol. 2006 Jul;17(7):1103-10
references.pmid: 16670204
references.citation: J Clin Oncol. 2008 Jan 10;26(2):303-12
references.pmid: 18182672
references.citation: N Engl J Med. 2001 Aug 30;345(9):690-2
references.pmid: 11547725
references.citation: J Clin Oncol. 2010 Feb 10;28(5):859-65
references.pmid: 20065174
references.citation: Oncology (Williston Park). 2007 Aug;21(9):1055-65; discussion 1065, 1070, 1075 passim
references.pmid: 17910311
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5620-7
references.pmid: 16009958
references.citation: Lancet Oncol. 2010 Mar;11(3):241-8
references.pmid: 20106720
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5721-7
references.pmid: 19001325
references.citation: J Clin Oncol. 2001 Apr 1;19(7):1976-84
references.pmid: 11283130
references.citation: Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38
references.pmid: 10421535
references.citation: Ann Surg. 2009 Mar;249(3):420-5
references.pmid: 19247029
references.citation: Surg Today. 2010 Jun;40(6):494-500
references.pmid: 20496129
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: Ann Oncol. 2005 Mar;16(3):425-9
references.pmid: 15677624
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: BMC Cancer. 2007 May 30;7:91
references.pmid: 17537235
references.citation: N Engl J Med. 2001 Aug 30;345(9):638-46
references.pmid: 11547717